Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Eon™ FR 1064 Full Abdomen Clinical Study Protocol

NCT04842110
View directory record Official record
Conditions
Abdominal Obesity
Interventions
Experimental: eonTM FR 1064 nm device
Device
Lead sponsor
Dominion Aesthetic Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Altamonte Springs, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 23, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

NCT04431635
View directory record Official record
Conditions
Indolent Lymphoma
Interventions
Copanlisib, Nivolumab, Rituximab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 23, 2026, 1:22 PM EDT
Approved For Marketing No phase listed Expanded access

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

NCT04395508
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
12
States / cities
Beverly Hills, California • San Francisco, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients

NCT00856791
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ON 01910.Na
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Analgesic Effect of IV Acetaminophen in Tonsillectomies

NCT01691690
View directory record Official record
Conditions
Adenotonsillitis, Tonsillitis
Interventions
Acetaminophen (paracetamol), Normal Saline Flush, Midazolam, Sevoflurane, Nitrous Oxide/Oxygen, Propofol, Morphine, Ondansetron, Dexamethasone
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
2 Years to 9 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function

NCT00845182
View directory record Official record
Conditions
Type 2 Diabetes, Healthy, Impaired Glucose Tolerance
Interventions
Pioglitazone, Exenatide, Pioglitazone and Exenatide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 23, 2026, 1:22 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of P-TIOX and Tixel Combined on Reducing Eye Wrinkles

NCT07222176
View directory record Official record
Conditions
Periocular Fine Wrinkles
Interventions
Split-Face Tixel Treatment With and Without Topical Peptide-Based Cosmeceutical (P-TIOX)
Combination Product
Lead sponsor
Main Line Center for Laser Surgery
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of Femring Estrogen Supplementation During Depo-Provera Initiation

NCT00563576
View directory record Official record
Conditions
Metrorrhagia
Interventions
Femring®, DepoProvera ®
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

NCT01354613
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions
Dobutamine, Amlodipine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

NCT06145035
View directory record Official record
Conditions
Ischemic Heart Disease
Interventions
umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Biological
Lead sponsor
Roberto Bolli
Other
Eligibility
21 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Miami, Florida • Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Virtual Reality in End Stage Kidney Disease

NCT06356168
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Social Virtual Reality, Individual Virtual Reality
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Terminated Phase 3 Interventional

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

NCT00016276
View directory record Official record
Conditions
Cardiac Toxicity, Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
Interventions
dexrazoxane hydrochloride, doxorubicin hydrochloride, cyclophosphamide, paclitaxel, trastuzumab, therapeutic conventional surgery, radiation therapy, tamoxifen citrate, laboratory biomarker analysis
Drug · Biological · Procedure + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

NCT06065176
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Interventions
Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Biological
Lead sponsor
Sarang K. Yoon, DO, MOH
Other
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional

Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes

NCT02315274
View directory record Official record
Conditions
Type 1 Diabetes, Pregnancy
Interventions
Frequent remote contact between clinic visits.
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Thrive Initiative Parent-Education Programming Study

NCT06823518
View directory record Official record
Conditions
Child Maltreatment, Parenting, Child Wellbeing
Interventions
Thrive Initiative Parent-Education Programming
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional

Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study

NCT07114718
View directory record Official record
Conditions
Congenital Heart Disease, Congenital Heart Disease (CHD)
Interventions
Ductus Arteriosus Stent
Device
Lead sponsor
Starlight Cardiovascular Inc
Industry
Eligibility
1 Minute to 6 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Deep Brain Stimulation Effects on Weight Change and Metabolic Rate

NCT01933113
View directory record Official record
Conditions
Obesity
Interventions
Deep Brain Stimulation of the Lateral Hypothalamic Area
Device
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Phase 2 Interventional

Multicenter Trial Evaluating the Safety and Efficacy of Autologous Volar Fibroblast Injection Into the Terminal Limb of Amputees.

NCT04839497
View directory record Official record
Conditions
Amputation
Interventions
Autologous Volar Fibroblast Injection into the Terminal Limb of Amputees
Combination Product
Lead sponsor
Major Extremity Trauma Research Consortium
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 1:22 PM EDT
Recruiting Not applicable Interventional

Optimizing Timing of Cesarean Delivery Consent on Labor and Delivery

NCT07117708
View directory record Official record
Conditions
Pregnancy, Informed Consent
Interventions
Early Surgical Consent, Surgical Consent if Clinically Indicated
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Terminated Phase 1 Interventional

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Non-Small Cell Lung Cancer, HER2-positive Colorectal Cancer, HER2-positive Tumors, HER2 Low Breast Cancer
Interventions
XMT-2056
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Celebration, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Tocilizumab to Treat Polymyalgia Rheumatica

NCT01396317
View directory record Official record
Conditions
Polymyalgia Rheumatica (PMR)
Interventions
Tocilizumab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 23, 2026, 1:22 PM EDT
Completed Not applicable Interventional Results available

Comparison of 3 Techniques for Ultrasound-guided Femoral Nerve Catheter Insertion

NCT00927368
View directory record Official record
Conditions
Total Knee Replacement Surgery
Interventions
ultrasound guidance alone, ultrasound guidance and needle stimulation, ultrasound guidance and catheter stimulation
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 23, 2026, 1:22 PM EDT